Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Biochaperone Combo;   Drug: Humalog Mix25;   Drug: Humalog;   Drug: Lantus;   Drug: Placebo
Sponsor:   Adocia
Recruiting - verified July 2015

Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Teneligliptin;   Drug: Sitagliptin
Sponsor:   Handok Pharmaceuticals Co., Ltd.
Not yet recruiting - verified July 2015

Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Device: Hypoxico Altitude Training Systems
Sponsor:   Pennington Biomedical Research Center
Not yet recruiting - verified July 2015

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
Sponsor:   Takeda
Not yet recruiting - verified August 2015

Tomography Emission Positron Assessment of Endothelial Dysfunction With the Waning of a Heart Attack in Patients With Diabetes Type II

Condition:   Myocardial Infarction
Intervention:   Other: Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)
Sponsor:   University Hospital, Caen
Recruiting - verified July 2015

Prevention of Type 2 Diabetes With Vitamin D

Condition:   Prediabetes
Interventions:   Dietary Supplement: vitamin D;   Dietary Supplement: Placebo
Sponsors:   Diabetes Foundation, India;   Department of Science and Technology
Recruiting - verified July 2015

Prevention of Type 2 Diabetes With Vitamin D Supplementation

Condition:   Prediabetes
Interventions:   Dietary Supplement: vitamin D + diet and lifestyle;   Dietary Supplement: Placebo + diet and lifestyle
Sponsors:   Diabetes Foundation, India;   Department of Science and Technology
Recruiting - verified July 2015

Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study

Conditions:   Diabetes Mellitus, Type 2;   Prediabetic State;   Intellectual Disability
Intervention:  
Sponsor:   University of Leicester
Recruiting - verified July 2015

The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus
Interventions:   Drug: thyroxine;   Drug: Placebo;   Other: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Sponsor:   Attikon Hospital
Completed - verified July 2015

Effects of Neuro-myo-electrical Stimulation on Insulin Sensitivity in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Device: acute muscle exercise by NMES;   Device: daily workout sequence with NMES in one week
Sponsor:   University Hospital, Caen
Completed - verified July 2015

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified July 2015

Glucose Response, Excursions And Treatment (GREAT) Study

Condition:   Type 2 Diabetes
Interventions:   Drug: DPPIV inhibitor -;   Device: Continuous glucose monitoring system.
Sponsors:   Royal Devon and Exeter NHS Foundation Trust;   NIHR Exeter Clinical Research Facility
Recruiting - verified July 2015

Mitigation of Type 2 Diabetes by Partial Ileal Bypass

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   East Carolina University;   Harvard Medical School;   Weill Medical College of Cornell University
Not yet recruiting - verified July 2015

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

Conditions:   Pain;   Chronic Pain;   Mental Disorders;   Cardiovascular Diseases;   Diabetes Mellitus, Type 2;   Arthritis
Interventions:   Other: Unblinded to Genetic Testing Results;   Other: Blinded to Genetic Testing Results
Sponsor:   Proove Bioscience, Inc.
Recruiting - verified July 2015

Impact of JuicePlus+ on the Health Status of an Overweight Stressed Population

Condition:   Inflammation
Interventions:   Dietary Supplement: Juice Plus+;   Other: Placebo
Sponsor:   University of Memphis
Recruiting - verified July 2015

Neck Grasp as a Predictor of Sleep Apnea

Conditions:   Obstructive Sleep Apnea;   Type 2 Diabetes
Interventions:   Other: polysomnogram;   Other: home sleep test;   Other: Easy Sleep Apnea Predictor
Sponsor:   Bassett Healthcare
Recruiting - verified June 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified July 2015

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin 338 (GIPET I);   Drug: insulin glargine;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified July 2015

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes

Condition:   Diabetes Mellitus
Interventions:   Drug: BIOD-531;   Drug: Humalog® Mix 75/25
Sponsor:   Biodel
Active, not recruiting - verified July 2015

EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects

Conditions:   Obesity;   Type 2 Diabetes
Intervention:   Device: EndoBarrier SANS
Sponsors:   GI Dynamics;   University Malaya Medical Centre, Lembah Pantai, 59100, Kuala Lumpur, Malaysia
Terminated - verified May 2015

The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control

Conditions:   Prediabetes;   Newly Diagnosed Type 2 Diabetes
Interventions:   Dietary Supplement: jerusalem artichoke and fermented soybeans powder mixture;   Dietary Supplement: placebo
Sponsor:   Yonsei University
Completed - verified July 2015

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: KD026;   Drug: Placebo;   Drug: Metformin
Sponsor:   Kadmon Corporation, LLC
Recruiting - verified July 2015

Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients

Conditions:   Microalbuminuria;   Microalbuminuria /Creatinine Ratios ACR
Interventions:   Drug: Saxagliptin;   Drug: glimepiride
Sponsor:   The Second Hospital of Nanjing Medical University
Enrolling by invitation - verified April 2015

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Condition:   Type II Diabetes
Interventions:   Drug: Farxiga;   Drug: Placebo;   Drug: Metformin;   Drug: Insulin
Sponsor:   AstraZeneca
Recruiting - verified July 2015

The Early Warning System for the Diabetic Encephalopathy

Conditions:   Diabetes Mellitus Type 2;   Mild Cognitive Impairment;   Metabolic Syndrome X
Intervention:  
Sponsor:   Tang-Du Hospital
Recruiting - verified July 2015

Add Glucokinase Activator to Target A1c

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: TTP399 400 mg;   Drug: TTP399 800 mg;   Drug: Sitagliptin 100 mg;   Drug: Placebo
Sponsor:   TransTech Pharma, LLC.
Recruiting - verified July 2015

A Hepatitis B With Hepatic Steatosis Study

Conditions:   Hepatitis B, Chronic;   Hepatic Steatosis
Intervention:  
Sponsors:   Fatty Liver and Alcoholic Liver Disease Study Group, China;   Unimed Scientific Inc.
Not yet recruiting - verified July 2015

Fatty Liver Disease Collaborative Research in China

Conditions:   Fatty Liver;   Fatty Liver, Alcoholic;   Non-alcoholic Fatty Liver Disease
Intervention:  
Sponsors:   Fatty Liver and Alcoholic Liver Disease Study Group, China;   Unimed Scientific Inc.
Not yet recruiting - verified July 2015

Effects of Personalized Dietary Advice on Health Status of Diabetes Type 2 Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Personalized Dietary Advice Services;   Behavioral: Regular care
Sponsors:   TNO;   Vitas;   SwissAnalysis
Active, not recruiting - verified August 2015

A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DA-1229_01;   Drug: E+M
Sponsor:   Dong-A ST Co., Ltd.
Completed - verified July 2015

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Pharmaceutical Care Program for Type 2 Diabetes Mellitus

Condition:   DIABETES MELLITUS, TYPE 2
Interventions:   Other: PHARMACEUTICAL CARE programe;   Other: Without PHARMACEUTICAL CARE programe
Sponsor:   TABREJ MUJAWAR
Recruiting - verified July 2015

Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified August 2015

Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Interventions:   Procedure: Bariatric surgery involving Roux-en-Y gastric bypass;   Procedure: Bariatric surgery involving Laparoscopic adjustable gastric banding;   Procedure: Bariatric surgery involving Laparoscopic sleeve gastrectomy
Sponsors:   The Cleveland Clinic;   Medtronic - MITG;   Ethicon, Inc.
Enrolling by invitation - verified July 2015

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Conditions:   Overweight;   Obesity
Interventions:   Device: Gelesis100;   Device: placebo
Sponsor:   Gelesis, Inc.
Recruiting - verified April 2015

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2963016;   Drug: LANTUS®;   Drug: Oral Antihyperglycemic Medication
Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim
Recruiting - verified July 2015

Weight Loss Program to Prevent Heart Disease

Conditions:   Insulin Resistance,;   Metabolic Syndrome;   Type 2 Diabetes
Intervention:   Behavioral: PilAm Go4Health Weight-loss Program
Sponsor:   University of California, San Francisco
Recruiting - verified July 2015

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Bydureon;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified August 2015

An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System

Condition:   Type 2 Diabetes
Intervention:   Device: EndoBarrier
Sponsor:   GI Dynamics
Withdrawn - verified November 2014

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified August 2015

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5 mg;   Drug: Placebo 5 mg for Saxagliptin;   Drug: Placebo 500 mg for metformin (with titration);   Drug: Metformin 500 mg with titration
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Fit and Trim for Diabetes Prevention

Conditions:   Pre-diabetes;   Overweight;   Obese
Intervention:   Behavioral: Filipinos Fit and Trim Weight Loss Program
Sponsors:   University of California, San Francisco;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2015

Investigating the Role of the Polyol Pathway in the Central Nervous System

Condition:   Hyperglycemia
Interventions:   Other: Brain MRS during hyperglycemic clamp;   Other: Analysis of Metabolites in cerebrospinal fluid
Sponsor:   Yale University
Recruiting - verified July 2015

Promoting the Universal Medication Schedule Via Mobile and EHR Technologies

Condition:   Type 2 Diabetes
Interventions:   Other: UMS Strategy;   Other: SMS Texting Reminders
Sponsors:   Northwestern University;   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

Phase 3 28 Week Study and 24 Week Extension to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Canagliflozin (TA-7284) +insulin;   Drug: Placebo+insulin
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified July 2015

A Study of Once-Daily RO6811135 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo QD;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Recruiting - verified July 2015

P4 Approach in Diabetes Type 2

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Intervention A: Diet;   Behavioral: Intervention B: Exercise;   Behavioral: Intervention C: Diet and Exercise
Sponsor:   W.J. Pasman
Enrolling by invitation - verified August 2015

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Sitagliptin
Sponsor:   Chipscreen Biosciences, Ltd.
Recruiting - verified July 2015

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified August 2015

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Placebo
Sponsor:   Chipscreen Biosciences, Ltd.
Recruiting - verified July 2015

The Effect of Walking Meditation Training on Glycemic Control and Vascular Function in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Other: Walking Meditation;   Other: Walking;   Other: No exercise
Sponsor:   Chulalongkorn University
Completed - verified August 2015

Metabolic Risk Following Gestational Diabetes Mellitus

Condition:   Gestational Diabetes
Intervention:   Other: Blood sampling and OGTT
Sponsor:   Hospices Civils de Lyon
Completed - verified July 2015

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5mg;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2015

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

Condition:   Focus Type 2 Diabetes Related Chronic Kidney Disease
Intervention:   Behavioral: Exercise
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified July 2015

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2014

Safety Evaluation of Adverse Reactions in Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Linagliptin;   Drug: Gliclazide
Sponsor:   Charles University, Czech Republic
Recruiting - verified July 2015

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Teneli (Teneligliptin) /Teneli;   Drug: Placebo/Teneli (Teneligliptin);   Drug: Insulin
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified July 2015

Nottingham Community Liver Biomarkers Cohort

Conditions:   Chronic Liver Disease;   Alcohol Use Disorder;   Type 2 Diabetes;   Persistently Elevated ALT;   Obesity
Intervention:   Device: Fibrosis Biomarkers
Sponsor:   University of Nottingham
Recruiting - verified July 2015

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified July 2015

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified July 2015

Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: glimepiride;   Drug: glargine and metformin
Sponsor:   Qifu Li
Recruiting - verified July 2015

Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes

Condition:   DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Intervention:   Behavioral: SMBG
Sponsors:   University of North Carolina, Chapel Hill;   Patient Centered Outcome Research Institute
Active, not recruiting - verified July 2015

Laser Treatment for Onychomycosis in Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Onychomycosis
Interventions:   Device: Laser Treatment YAG laser;   Drug: Standard Treatment (control group) terbinafine hydrochloride tablets
Sponsors:   BCDiabetes.Ca;   BritaMed, Inc.
Not yet recruiting - verified July 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified July 2015

DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Hamad Medical Corporation;   Weill Cornell Medical College in Qatar
Recruiting - verified July 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified July 2015

Influence of Bariatric Surgery on Serum Levels of 26RFa

Conditions:   Diabetes;   Obesity
Intervention:   Behavioral: Meal test taking and hormones measure including 26RFa
Sponsors:   University Hospital, Rouen;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified July 2015

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: lixisenatide AVE0010;   Drug: biguanide;   Drug: TZD;   Drug: alpha-GI;   Drug: glinide
Sponsor:   Sanofi
Completed - verified August 2015

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

GLP-1 and Hypoglycemia

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion;   Other: Placebo Comparator: Saline Infusion
Sponsor:   University of Maryland
Recruiting - verified July 2015

Genetics of Insulin and Incretins in Cystic Fibrosis

Condition:   Cystic Fibrosis
Interventions:   Genetic: Blood or Saliva Sample Collection;   Other: Glucose -potentiated arginine (GPA) stimulation tests
Sponsors:   Children's Hospital of Philadelphia;   University of Pennsylvania
Recruiting - verified July 2015

Osteoprosis in Type 2 Diabetic Patients- a Cohort Study

Conditions:   Type 2 Diabetes Mellitus;   Osteoporosis
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting - verified July 2015

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Condition:   Type 2 Diabetes in Obese Subjects
Interventions:   Device: EndoBarrier;   Procedure: Sham Procedure
Sponsor:   GI Dynamics
Terminated - verified October 2014

The Health Influences of Puberty (HIP) Study

Conditions:   Obesity;   Insulin Resistance;   Gonadal Dysfunction;   Type 2 Diabetes
Intervention:   Drug: Metformin
Sponsors:   University of Colorado, Denver;   American Diabetes Association;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Children's Hospital Colorado
Recruiting - verified July 2015

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2015

Diabetes Outcomes and Nurse Case Manager Study

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Nurse Case Management;   Behavioral: standard diabetologist care
Sponsors:   BCDiabetes.Ca;   Sanofi
Completed - verified July 2015

Resistance Training and Testosterone After Spinal Cord Injury

Condition:   Spinal Cord Injury
Interventions:   Procedure: Resistance Training and Testosterone Patches;   Drug: Testosterone Patches
Sponsors:   Department of Veterans Affairs;   Virginia Commonwealth University
Active, not recruiting - verified July 2015

The VALDIATE-D Study

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Drug: Calcitriol and Lisinopril;   Drug: Placebo
Sponsor:   Brigham and Women's Hospital
Recruiting - verified July 2015

Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin

Conditions:   Polycystic Ovary Syndrome;   Insulin Resistance
Interventions:   Drug: Metformin;   Drug: Clomiphene citrate
Sponsor:   OVO R & D
Withdrawn - verified July 2015

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Conditions:   Coronary Artery Disease;   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsor:   Haugaard, Steen Bendix, M.D., DMSc
Completed - verified July 2015

Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin

Condition:   Type 2 Diabetes
Interventions:   Drug: Vildagliptin;   Drug: Placebo
Sponsor:   Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète
Completed - verified July 2015

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Metformin Rescue;   Drug: Sitagliptin Rescue;   Biological: Insulin Rescue;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2015

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Condition:   Type 2 Diabetes
Interventions:   Drug: ITCA 650;   Other: ITCA placebo
Sponsor:   Intarcia Therapeutics
Active, not recruiting - verified July 2015

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: ITCA 650 60 mcg/day;   Drug: sitagliptin
Sponsor:   Intarcia Therapeutics
Completed - verified July 2015

Effectiveness of Individualized Exercise Program, Combined With a Balanced Diet on the Evolution of Body Fat

Condition:   Obesity
Interventions:   Behavioral: LIPOXmax;   Behavioral: 60% VO2peak;   Behavioral: Good Medical Practices;   Dietary Supplement: supplementation in fruits and vegetables
Sponsor:   Centre Hospitalier Universitaire de la Réunion
Completed - verified July 2015

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified August 2015

Two Years Maintenance of Structured Group Self-management Education in Type 2 Diabetes : a Randomized Controlled Trial

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Structured self-management group education during 2 years
Sponsors:   Centre Hospitalier Universitaire de la Réunion;   Ministry of Health, France
Active, not recruiting - verified July 2015

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

Conditions:   Depression;   Impaired Glucose Tolerance
Interventions:   Other: The Blues Program;   Other: Hey Durham
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health Clinical Center (CC)
Active, not recruiting - verified March 2015

Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Paricalcitol;   Other: placebo
Sponsors:   Mario Negri Institute for Pharmacological Research;   Abbott
Completed - verified July 2015

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Diabetic Patients With Aortocoronary Bypass

Conditions:   Coronary Artery Disease;   Left Ventricular Dysfunction;   Type 2 Diabetes Mellitus
Intervention:   Drug: Exenatide
Sponsors:   Charles University, Czech Republic;   Eli Lilly and Company
Completed - verified July 2015

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation - verified July 2015

Xanthohumol and Metabolic Syndrome

Condition:   Metabolic Syndrome
Intervention:   Dietary Supplement: Xanthohumol
Sponsors:   Oregon State University;   Oregon Health and Science University;   National Center for Complementary and Integrative Health (NCCIH)
Completed - verified July 2015

Home Exercise for Older Diabetics

Condition:   Diabetes Mellitus Type 2
Interventions:   Behavioral: home exercise/physical activity (PA) enhancement program with behavioral support;   Behavioral: flex and toning health education program
Sponsor:   Department of Veterans Affairs
Active, not recruiting - verified July 2015

JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Janumet, Lantus;   Drug: metformin, gliclazide, protaphane
Sponsor:   Chinese University of Hong Kong
Completed - verified July 2015

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified August 2015

Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes

Conditions:   Overweight;   Obesity;   Type 2 Diabetes
Interventions:   Behavioral: Caloric restriction;   Behavioral: Diet intervention and structured exercise training program
Sponsor:   Institut de Recherches Cliniques de Montreal
Recruiting - verified July 2015

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Comparator: placebo to pioglitazone;   Drug: Comparator: placebo to Sitagliptin;   Drug: Comparator: pioglitazone;   Drug: Glimepiride or gliclazide;   Drug: Metformin;   Drug: Pioglitazone rescue therapy
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified July 2015

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

Conditions:   Nonalcoholic Steatohepatitis;   Nonalcoholic Fatty Liver Disease;   Type 2 Diabetes Mellitus
Interventions:   Drug: Pioglitazone;   Drug: Placebo;   Drug: Pioglitazone;   Drug: Placebo
Sponsors:   University of Florida;   The University of Texas at San Antonio
Completed - verified July 2015

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Comparator: Placebo;   Drug: Pioglitazone;   Drug: Metformin;   Drug: Glipizide
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Intervention:   Biological: CVX-096
Sponsor:   Pfizer
Completed - verified July 2015

An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Intervention:   Drug: VIAject™
Sponsor:   Biodel
Completed - verified July 2015

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

Conditions:   Weight Loss;   Obesity
Interventions:   Drug: Byetta (exenatide);   Behavioral: Weight loss;   Other: Metabolic Chamber;   Drug: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2014

Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.

Condition:   Type 2 Diabetes
Interventions:   Drug: Regular Human Insulin;   Drug: Insulin Lispro;   Drug: Insulin VIAject™ (75%);   Drug: Insulin VIAject™ (90%)
Sponsor:   Biodel
Completed - verified July 2015

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

Condition:   Weight Gain
Intervention:   Drug: Exenatide
Sponsors:   University of Cincinnati;   Eli Lilly and Company
Completed - verified August 2015

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sitagliptin phosphate;   Drug: metformin hydrochloride;   Drug: Comparator: placebo sitagliptin;   Drug: Comparator: placebo metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-0941;   Drug: Placebo;   Drug: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Comparator: Sitagliptin phosphate;   Drug: Comparator: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

Training Effects on Skeletal Muscle Fatty Acid Metabolism

Condition:   Healthy Volunteers
Interventions:   Drug: 20% lipid infusion;   Drug: glycerol
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Completed - verified July 2015

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: Placebo;   Drug: Comparator: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Dietary Supplement: American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer);   Dietary Supplement: American Ginseng (Panax quinquefolius L.);   Dietary Supplement: Wheat Bran
Sponsors:   St. Michael's Hospital, Toronto;   Canadian Diabetes Association
Active, not recruiting - verified July 2015

Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Pomegranate Juice;   Dietary Supplement: Placebo Juice
Sponsors:   University of Colorado, Denver;   POM Wonderful LLC
Completed - verified July 2015

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified August 2015

Duodenal Exclusion for the Treatment of Type 2 Diabetes

Condition:   Diabetes
Intervention:   Procedure: Duodenal Exclusion
Sponsor:   Medtronic - MITG
Withdrawn - verified July 2015

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Conditions:   Diabetic Nephropathy;   Diabetes Mellitus;   Diabetic Kidney Disease;   Albuminuria
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2015

Coronary CT Angiography in Asymptomatic Diabetes Mellitus

Condition:   Diabetes Mellitus
Intervention:   Other: Imaging study, No intervention
Sponsors:   Carmel Medical Center;   European Foundation for the Study of Diabetes
Active, not recruiting - verified February 2015

Depression-Diabetes Mechanisms: Urban African Americans

Conditions:   Diabetes;   Depression
Interventions:   Behavioral: Beating the Blues;   Drug: Escitalopram;   Drug: Placebo
Sponsors:   Emory University;   National Institute of Mental Health (NIMH)
Completed - verified July 2015

Get CardioSmart

You're Invited